| Ytd | -62.26% | |
| 1y | -89.90% |
| Open | 1.38 | Prev Close | 1.37 | Low | 1.33 | High | 1.38 | Mkt Cap | 6.13M |
| Vol | 38.53K | Avg Vol | 158.36K | EPS | -12.18 | P/E | N/A | Forward P/E | -0.22 |
| Beta | 0.47 | Short Ratio | 0.31 | Inst. Own | 7.06% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 04-23 | Earning | 08-15 | 50-d Avg | 1.41 | 200-d Avg | 2.85 | 1yr Est | 8.32 |
ENVB News
Enveric Biosciences (NASDAQ:ENVB) reported quarterly losses of $(0.76) per share. This is a 93.47 pe
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),
Biotechnology firm Enveric Biosciences (NASDAQ:ENVB) revealed additional preclinical findings reinfo
Enveric Biosciences reports new preclinical data supporting the non-hallucinogenic profile of its le
Preclinical testing of EB-003 was conducted using a targeted, highly sensitive GloSensor™ cAMP assay
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),
Enveric Biosciences (NASDAQ: ENVB) (âEnvericâ or the âCompanyâ), a biotechnology company adv
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),
Studies are designed to evaluate the potential for the compound to interact with DNA and cause genet
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),
Enveric Biosciences (NASDAQ: ENVB) (âEnvericâ or the âCompanyâ), a biotechnology company adv
Enveric Biosciences (NASDAQ:ENVB) reported quarterly losses of $(1.08) per share. This is a 92.62 pe
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),
Enveric highlights EB-003 PTSD data as Trump-backed psychedelic research signals rising demand for n
Enveric Biosciences today highlighted preclinical data for its lead candidate, EB-003, a dual 5-HT2A
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),
Appointment strengthens Board with seasoned public company biotech executive following recent Nasdaq
Enveric Biosciences, Inc (NASDAQ:ENVB) stock is trading higher on Friday after the U.S. Food and Dru
The FDA issues priority vouchers and clears early trials for ibogaine derivatives for using psychede
https://www.hhs.gov/press-room/fda-accelerates-action-treatments-serious-mental-illness-following-ex
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),
Enveric surged more than 92% in premarket trading as investors rushed into psychedelic‑focused biote
US stocks down at midday, Dow down 0.2%, NASDAQ down 0.52%. Energy up 1.1%, consumer discretionary d
US stocks mixed, energy shares climb. Cleveland-Cliffs falls 6% after reporting Q1 results. Enveric
Psychedelic drug maker shares jumped in Monday pre-market after an order from President Donald Trump
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Compa
Blaize Holdings rose 24.3% in pre-market trading on $50M contract with NeoTensr & MOU with Winma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Compa
https://www.cbsnews.com/news/psychedelic-drug-ibogaine-ptsd-trump-to-sign-executive-order/
https://www.marijuanamoment.net/bipartisan-senators-file-bill-to-support-psychedelics-research-and-t
